By Kwok Chow, PhD, and Mark J Kontny, PhD
Approval of new drug products that treat unmet medical needs held steady or declined over the last decade.
Meanwhile, pharma companies continue to consolidate, R&D budgets continue to decline, and the cost of conducting late-stage clinical trials continues to escalate.
This article summarises techniques for formulating poorly water-soluble APIs and how selecting the right outsourcing partner can accelerate development.
Download to read more.
By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.